Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus CONRAY 43.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus CONRAY 43.
CHOLETEC vs CONRAY 43
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
1 gram intravenously every 8 hours; maximum 3 g/day.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent